Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) shares were up 5.7% on Tuesday . The company traded as high as $0.40 and last traded at $0.37. Approximately 1,123,072 shares traded hands during trading, an increase of 28% from the average daily volume of 879,308 shares. The stock had previously closed at $0.35.

A number of research analysts have weighed in on TRIL shares. HC Wainwright reduced their target price on Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Zacks Investment Research upgraded Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Thursday, April 25th.

The firm has a market capitalization of $7.38 million, a price-to-earnings ratio of -0.16 and a beta of 2.44.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last posted its earnings results on Monday, March 11th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.24. As a group, research analysts expect that Trillium Therapeutics Inc will post -1.75 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Trillium Therapeutics by 164.0% in the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 16,541 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Trillium Therapeutics in the 4th quarter worth approximately $35,000. Jane Street Group LLC bought a new stake in shares of Trillium Therapeutics in the 4th quarter worth approximately $43,000. Oxford Asset Management LLP boosted its position in shares of Trillium Therapeutics by 64.0% in the 1st quarter. Oxford Asset Management LLP now owns 93,589 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 36,534 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Trillium Therapeutics by 25.2% in the 3rd quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after purchasing an additional 71,860 shares in the last quarter. Hedge funds and other institutional investors own 33.00% of the company’s stock.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/trillium-therapeutics-tril-trading-up-5-7/3031612.html.

Trillium Therapeutics Company Profile (NASDAQ:TRIL)

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Featured Article: Coverage Ratio

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.